What is the first line treatment for Leprosy (Paucibacillary)?

The first-line treatment for Paucibacillary leprosy involves the combination of Dapsone and Rifampin. This regimen is specifically recommended because it effectively targets the Mycobacterium leprae bacterium, which causes leprosy. Dapsone works as a sulfone antibiotic that inhibits bacterial folate synthesis, while Rifampin is a potent rifamycin antibiotic that inhibits bacterial RNA synthesis. The combination of these two medications ensures a synergistic effect, which is essential for effectively managing the infection and preventing resistance.

This treatment approach is aligned with the World Health Organization's guidelines for leprosy management, emphasizing the importance of multimodal therapy for effective patient outcomes. In cases of Paucibacillary leprosy, this dual therapy is particularly important as it reduces the risk of transmission and promotes healing of the skin lesions associated with the condition.

Other treatments listed are not applicable for leprosy. For example, Griseofulvin is primarily used for dermatophyte infections of the skin, hair, and nails; Amphotericin B is an antifungal used for serious fungal infections; and topical antifungals address localized fungal infections but have no role in treating leprosy. Thus, the combination of D